RecruitingNot ApplicableNCT05206682
Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect
Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Enrollment
94 participants
Start Date
May 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
GnRH-a will be used to postpone period after vaginal repair for Cesarean Section Scar Defect（CSD） patients with adenomyosis which will be compared with CSD patients with adenomyosis who receive transvaginal surgery without GnRH-a, whether delayed period improving the CSD prognosis will be assessed.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 50 Years
Inclusion Criteria7
- Clearly diagnosed with CSD complicated with adenomyosis
- Experiencing clinical features of abnormal uterine bleeding, prolonged menstrual flow (the duration of menstruation is more than 10 days).
- The thickness of the remaining muscular layer of CSD was less than 3 mm.
- Normal range of blood sugar and insulin
- No serious medical problems (important viscera function in the normal range).
- uterine fibroids no more than 5cm
- Sign the informed consent.
Exclusion Criteria7
- Indefinite diagnosis.
- Malignant tumors.
- With severe medical problems (severe liver disease, kidney disease, respiratory diseases, heart disease or uncontrolled diabetes, epilepsy, etc., dysfunction of important organs).
- Pregnant.
- Mental diseases.
- Allergy to the any ingredients of Leuprorelin
- Unwilling to comply with the research plan.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLeuprorelin
Leuprorelin will be used to postpone period after vaginal repair.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05206682